Urolog. pro Praxi, 2006; 3: 108-110

Benefit of nifuratel in treating acute uncomplicated urinary tract infections

MUDr. Jiří Kladenský¹, RNDr. Věra Toršová CSc², RNDr. Eva Chmelařová²

¹ Urologická ambulance, Dům zdraví, Brno

² Antibiotické středisko, Krajská hygienická stanice, Ostrava

Urinary tract infections are considered to be the most common bacterial infections which occur with varying frequency throughout lifetime in both sexes. The main causative agents of acute lower urinary tract infections are primarily the uropathogenic strains of Escherichia coli. In addition to clinical symptomatology, assessment of bacteriuria and determination of sensitivity to appropriate antibiotics is of essential importance for treatment. Since this requirement cannot always be met, it is necessary to accept empiric therapeutic regimens provided that the results of long-term observation of sensitivity of major urinary pathogens to the antibiotics used are available. Nitrofuran chemotherapeutics meet these criteria as they have a wide antibacterial spectrum including all common causative agents of acute urinary tract infections and pose a minimal risk of resistance development. Nifuratel exhibits an antibacterial effect similar to that of nitrofurantoin but is much better tolerated with only a rare occurrence of adverse effects. In addition, it is effective against Trichomonas vaginalis, Chlamydia trachomatis and Candida spp. There are no teratogenic or mutagenic effects and it can be used from the second trimester of pregnancy and during lactation. It has been shown to have very good clinical efficacy in treating acute urinary tract infections and vulvovaginitides.

Keywords: Nifuratel, wide-spectrum chemotherapeutic agent, acute urinary tract infections, vulvovaginitides, efficacy, safety, tolerance

Published: August 1, 2006  Show citation